{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Khojah A"],"funding":["NCATS NIH HHS","NIAMS NIH HHS"],"pagination":["20-25"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11221785"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["5"],"pubmed_abstract":["This study investigates HLA-DR expression on activated T cells and serum neopterin levels in Juvenile Dermatomyositis (JDM) children pre- and post-treatment. Sixty-nine JDM children (less than 18 years) were included. Elevated HLA-DR+ <i>T</i> cells (>7 %) were observed in 19 % of untreated cases. Post-treatment, mean HLA-DR+ <i>T</i> cells decreased from 5.1 to 2.9 (<i>P</i> < 0.001), and serum neopterin levels declined from 19.3 to 9.1 nmol/L (<i>P</i> < 0.0001). A positive correlation between serum neopterin and HLA-DR T cell percentage was observed (<i>r</i> = 0.39, <i>P</i> = 0.01). Intravenous steroid treatment exhibited a 47.4 % improvement in HLA-DR+ <i>T</i> cells and a 50.5 % reduction in serum neopterin levels, in contrast to 14.8 % and 34.1 % in the oral steroid group. In concl"],"journal":["Clinical immunology communications"],"pubmed_title":["Increased percentage of HLA-DR T cells in untreated juvenile dermatomyositis."],"pmcid":["PMC11221785"],"funding_grant_id":["UL1 TR001422","R21 AR077565"],"pubmed_authors":["Khanolkar A","Schutt M","Bensen N","Morgan G","Bukhari A","Pachman LM","Khojah A"],"additional_accession":[]},"is_claimable":false,"name":"Increased percentage of HLA-DR T cells in untreated juvenile dermatomyositis.","description":"This study investigates HLA-DR expression on activated T cells and serum neopterin levels in Juvenile Dermatomyositis (JDM) children pre- and post-treatment. Sixty-nine JDM children (less than 18 years) were included. Elevated HLA-DR+ <i>T</i> cells (>7 %) were observed in 19 % of untreated cases. Post-treatment, mean HLA-DR+ <i>T</i> cells decreased from 5.1 to 2.9 (<i>P</i> < 0.001), and serum neopterin levels declined from 19.3 to 9.1 nmol/L (<i>P</i> < 0.0001). A positive correlation between serum neopterin and HLA-DR T cell percentage was observed (<i>r</i> = 0.39, <i>P</i> = 0.01). Intravenous steroid treatment exhibited a 47.4 % improvement in HLA-DR+ <i>T</i> cells and a 50.5 % reduction in serum neopterin levels, in contrast to 14.8 % and 34.1 % in the oral steroid group. In concl","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jun","modification":"2025-04-04T12:53:49.777Z","creation":"2025-04-04T12:53:49.777Z"},"accession":"S-EPMC11221785","cross_references":{"pubmed":["38962376"],"doi":["10.1016/j.clicom.2024.02.002"]}}